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Whilst the amino acid sequence of a protein is determined by its gene sequence, the final structure and function are determined
by posttranslational modifications (PTMs), including quality control (QC) in the endoplasmic reticulum (ER) and during passage
through the Golgi apparatus. These processes are species and cell specific and challenge the biopharmaceutical industry when
developing a production platform for the generation of recombinant biologic therapeutics. Proteins and glycoproteins are also
subject to chemical modifications (CMs) both in vivo and in vitro. The individual is naturally tolerant to molecular forms of self-
molecules but nonself variants can provoke an immune response with the generation of anti-drug antibodies (ADA); aggregated
forms can exhibit enhanced immunogenicity and QC procedures are developed to avoid or remove them. Monoclonal antibody
therapeutics (mAbs) are a special case because their purpose is to bind the target, with the formation of immune complexes
(ICs), a particular form of aggregate. Such ICs may be removed by phagocytic cells that have antigen presenting capacity. These
considerations may frustrate the possibility of ameliorating the immunogenicity of mAbs by rigorous exclusion of aggregates from
drug product. Alternate strategies for inducing immunosuppression or tolerance are discussed.
1. Introduction
The modern era of biologic therapeutics may be identified
with the FDA approval of recombinant insulin (Humulin)
in 1982, produced in E. coli, and recombinant erythropoietin
(EPO) in 1989 (Epogen); since glycosylation of EPO is
essential to its function it was, necessarily, produced in a
mammalian cell line (a Chinese hamster ovary (CHO) cell
line). Despite extensive clinical experience adverse reactions
to these recombinant molecules are still encountered, ∼2%
for insulin [1] and rarer, but more devastating, for EPO [2].
These incidences are frequently due to the patient devel-
oping antibodies that are specific for the therapeutic and
neutralising its activity (anti-drug antibodies (ADA): anti-
therapeutic antibodies (ATA)). The development of ADA
suggests that the therapeutic is being recognized as “foreign”
(nonself) by the patient’s immune system, due to the presence
of molecules that exhibit structural features different to those
of the endogenous protein/glycoprotein (P/GP). Ironically,
a high incidence of ADA is encountered for recombinant
antibody therapeutics (mAb/s); this is due, in part, to the
fact that each mAb therapeutic is selected for unique epitope
specificity and consequently exhibits unique structure.
The starting point for the generation of recombinant
P/GPs requires determination of the primary, secondary, and
tertiary structure of the endogenous (natural) molecule. This
is not a trivial exercise since whilst the gene sequence deter-
mines the primary amino acid sequence it does not provide
a guide to the precise structure of the active molecule. The
nascent polypeptide chain may be subject to cotranslational
modifications (CTMs) as it is extruded from the ribosome
tunnel, for example, the addition of oligosaccharide; editing
for correct folding and initial oligosaccharide processing
take place within the endoplasmic reticulum and further
posttranslational modifications (PTMs) are effected during
passage through the Golgi apparatus. The P/GPs that exit
the Golgi may be trafficked within the cell, inserted in the
plasmamembrane, or secreted into the extracellular environ-
ment. The functional activity of a P/GP may be dependent
on subsequent chemical modifications (CMs), for example,
phosphorylation, and further CMs that constitute its “aging”
and subsequent catabolism [3]. It is important to emphasise,
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therefore, that endogenous (native!) P/GPs exhibit structural
heterogeneity. These heterogeneities are compounded when
establishing the structure of a purified formof a P/GPbecause
additional heterogeneities are introduced during its isolation,
purification, and characterization; in addition the purer the
isolated protein is, the lower the yield is and the less certain
one can be that it is representative of the active endogenous
molecule in vivo.
2. Overview of Co- and
Posttranslational Modifications
Variations in protein structure from that predicted by open
reading frame gene sequences may be introduced during
transcription and/or translation, by misincorporation at the
DNA, RNA, and amino acid level, and the introduction
of CTMs [4–10]. Commonly encountered CTMs/PTMs and
CMs include glycosylation, phosphorylation, sulphation, gly-
cation, deamidation, and deimination [4, 5]. Additionally, the
structural profile, in vivo, may vary with age, sex, health, and
disease.Thehuman genome contains∼21,000 genes encoding
expressed proteins; however, it is estimated that the human
proteome may be comprised of 1-2 million protein entities,
due to the PTMs/CTMs that are essential to physiological
function, systemically, and/or microenvironments [4, 5].
Each human individual should, in theory, be immunologi-
cally tolerant to all molecules within their proteome, includ-
ing all isoforms exhibiting natural PTMs and CMs; however,
the exquisite sensitivity of the current generation of assay
technologies allows the detection of low affinity antibody
to many self-antigens in healthy individuals. Paradoxically,
antibodies having the same, or similar, specificity may be
amplified in disease states and be a diagnostic marker for
individual disease entities [11]. Developments in qualitative
and quantitative mass spectrometry during the past decade
have “revolutionized” the enumeration of PTMs and CMs
generating P/GP heterogeneity and defined >300 structural
CTM/PTMs [12–15]. Analysis of 530,264 sequences in the
Swiss-Prot database was shown to yield 87,308 experimen-
tally identified PTMs and 234,938 putative PTMs [15]. The
potential for structural and functional complexity can be
appreciated from the fact that the human genome encodes
518 protein kinases and 200 phosphatases [16, 17].The second
most frequent CTM/PTM is glycosylation. Oligosaccharides
may be attached to asparagine residues to generate N-linked
glycoproteins or to the hydroxyl groups of serine, threonine,
or tyrosine to generate O-linked glycoforms. The N-linked
repertoire contains >500 different oligosaccharide structures
that may be differentially attached at multiple glycosylation
sites to generate >1000 different types of glycan, a conse-
quence of the activities of >250 glycosyltransferases [5, 6, 18,
19].
The potential for complexity/heterogeneity can be illus-
trated for recombinant mAbs. The full length sequence of
an IgGmolecule includes∼40 asparagine/glutamine residues;
therefore, random deamidation of one of these residues will
generate 40 structural variants (isoforms); deamidation of
two residues may generate 40 × 40 = 1,560 variants; three:
40 × 1,560 = 59,280 variants; and so forth. When all potential
PTMs are considered it has been calculated that a full length
IgG molecule may exhibit a heterogeneity embracing 108 iso-
forms [20]. RecombinantmAbs present a particular challenge
since each exhibit a unique structure and must be evaluated
on a “case-by-case” basis. Fortunately, current technologies
allow for early screening and selection of clones that do
not have amino acid residues susceptible to PTM/CTMs
within their complimentary determining regions (CDRs);
other criteria may be selected to optimise solubility, stability,
and so forth. The constant region sequence can also be
selected, that is, Ig class and subclass, to define the final
drug substance/product developed. A biosimilar candidate
must be demonstrated to be structurally and functionally
comparable to the innovator product [21, 22].
The starting point for development of a recombinant
P/GP therapeutic is the consensus structure of the “wild-
type” (WT) molecule. It is required that a candidate recom-
binant P/GP therapeutic exhibits PTMs comparable to those
of the consensus WT structure and an absence of unnatural
PTMs introduced by the production process. Structural iden-
tity with the WT P/GP may not be possible since production
platforms employ nonhuman tissues (CHO, NS0, Sp2/0 cells,
etc.) and the secreted P/GP is exposed to the culture medium
and products of intact and effete producer cells over an
extended period, prior to rigorous downstream purification,
formulation, and storage conditions. Any departure from
the consensus WT structure may be perceived as nonself by
the immune system and result in the generation of ADA.
Production in a prokaryotic system (e.g., E. coli) may result
in a protein being recovered as an inclusion body that has
to be solubilized and refolded in vitro to yield a product that
may lack natural PTMs or bear unnatural ones. This system
may be purposely exploited to develop novel therapeutics,
for example, aglycosylated full length antibody molecules
that may act as agonists or antagonists but not provoke
downstream effector activities. Comparison of the structure
of a candidate antibody therapeutic with aWT counterpart is
not possible due to the unique structure of its variable regions;
however, the amino acid sequence of the constant regions and
potential glycoform profiles are established.
Approval of a candidate P/GP therapeutic is dependent
on the demonstration of clinical efficacy for a product that has
been structurally characterized employing multiple orthogo-
nal physicochemical techniques [23, 24]. The physicochemi-
cal characteristics established define the drug substance and
drug product and must be maintained throughout the life
cycle of an approved drug. Critical Quality Attributes (CQAs)
that define drug efficacy are defined [25] and maintained
within the production platform developed [26]. These data
are the undisclosed intellectual property of an innovator
company and it is deemed essentially impossible to produce
an identical product employing a similar or alternative plat-
form within another facility; that is, in principle, it is not
possible to develop generic biopharmaceuticals. It is possible
to introduce improvements in the production process that
result in changes in structural parameters if it is demon-
strated not to compromise drug efficacy and patient benefit.
Importantly, each drug will be assigned a “shelf-life,” that is, a
period of time after which physicochemical changes may be
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evident which impact biologic activity and limit its efficacy
and/or prejudice patient benefit. Accelerated storage studies
under varying conditions establish structural and functional
stability and guide formulation to provide an acceptable shelf-
life.
3. Immunogenicity
As previously stated endogenous P/GPs may be present in
vivo in multiple structural isoforms and it may be possible
to demonstrate the presence of self-reactive antibodies in
serum; however, a healthy individual is functionally tolerant,
that is, asymptomatic. Within a disease state the quantitative
and qualitative nature of the PTM/CTM repertoire may be
amplified with consequent generation of immune complexes
and/or aggregated forms that are engulfed by phagocytic
cells that have the capacity to process and present antigens,
with consequent induction or amplification of an anti-self-
response [11, 27–30].
A “casebook” example that may be cited is the antic-
itrullinated protein response, accepted as the most spe-
cific biomarker for rheumatoid arthritis (RA). Citrullinated
proteins are generated by the action of peptidylarginine
deiminases (PADs), which convert arginine into citrulline in
a process called citrullination or deimination [31–33]. This is
a natural process; however, in RA, it is amplified and several
citrullinated proteins are present within inflamed synovial
tissue. It is possible that within the milieu of inflammation
some proteins may be denatured and arginine residues that
are not normally exposed become accessible to citrullination
and may be “seen” as nonself by the immune system. The
specificity of this response is reflected in the fact that the diag-
nostic assay employs a cyclic citrullinated peptide as antigen:
the anti-citrullinated peptide antibody (ACPA) response [34,
35]. Importantly, increased levels of ACPA may be detected
in advance of clinical manifestations. More recently the pres-
ence of anti-carbamylated protein (anti-CarP) autoantibodies
have shown specificity for RA and their presence to overlap, at
least in part, with ACPA activity: however, anti-CarP-positive
and ACPA-negative patients have been described [36–38].
Carbamylated protein arises from the action of cyanate on
the epsilon amino groups of lysine residues to generate
homocitrulline; cyanate is generated in vivo by several routes
and its production is enhanced in inflammation.
The original recombinant erythropoietin (EPO) drug
(Epogen) was introduced in 1988 and has been used suc-
cessfully worldwide; however, incidences of neutralising anti-
EPO ADA have been reported with the development of pure
red cell aplasia (PRCA).With the expiry of the original patent
various alternative EPOs have been approved and additional
incidences of PRCA reported. A meta-analysis published in
2008 identified 215 cases, worldwide, of ADA and consequent
PRCA; 189 of the patients were exposed to Eprex only [39,
40]. In 1998 a “cluster” of PRCA incidences was reported in
Europe and investigation revealed variations in formulation
of the EPO associated with the absence of human serum
albumin (HSA), subcutaneous administration, and capping
with an uncoated rubber stopper [40, 41]. It was posited that
the net result was likely to be chemical modification and/or
aggregation of a critical proportion of the therapeutic; aggre-
gation is considered to be a principle PTM/CM resulting in
immunogenicity and the initiation of ADA responses.
Anticipating the patent expiry date of an approved
biologic therapeutic the innovator company may develop a
variant having enhanced properties and submit for approval
and further patent protection.Other biopharmaceutical com-
panies may similarly anticipate patent expiry and seek to
develop a copy of the original innovator product, not claimed
to be the same but biosimilar, or comparable [25, 26]. Numer-
ous EPO biosimilars have been approved in Europe and
the USA and, due to their competitive pricing, have gained
market penetration. Copies of EPO have also been generated
outside of Europe/USA; however, not all have been rigorously
examined by a regulatory authority; others that have not
been submitted to a regulatory authority for approval may
be marketed as a biosimilar. Cumulative incidences of PRCA
have been reported fromThailand where investigations iden-
tified EPOproducts that did notmeet international standards
and/or were illegal, having been smuggled into the country
[41–43].
4. Protein Aggregation and Immunogenicity
Early studies investigating the capacity of the immune system
to produce specific antibody responses employed potential
immunogens of differing molecular weight (MW) and size,
from small molecule chemicals to protein antigens and
their denatured aggregated forms. These studies suggested
a threshold for immunogenicity of ∼10 kDa; below this
MW immune responses could be elicited if the molecule is
presented conjugated to a macromolecule, in which case the
chemical is termed a hapten. HighMWproteins (e.g., bovine
serum albumin; MW ∼60 kDa) proved to be immunogenic
when delivered together with an adjuvant or in aggregated
form. These principles have been validated and extended
particularly in relation to vaccine research and development
[44].
The biotherapeutics considered in this review are P/GPs
having an overall structure (conformation) that confers solu-
bility in aqueous solutions. The integrity (stability) of a P/GP
molecule is contributed to by a core of hydrophobic amino
acid side chains buried within the internal space of the mole-
cule; however, some such side chains may be only partially
buried and form hydrophobic patches on the surface of
the molecule. Similarly, most hydrophilic amino acid side
chains are exposed on the surface of a molecule but may also
be partially buried. Maintenance of structural integrity is
essential to function and it is posited that all soluble P/GPs are
susceptible to the formation of insoluble fibrillar aggregates
under specific denaturing conditions. However, the individ-
ual is normally protected by an essential editing function per-
formed within the endoplasmic reticulum (ER) that allows
only correctly folded protein to transfer to the Golgi appara-
tus;misfolded protein activates the unfolded protein response
(UPR) and enzymatic degradation within the proteasome
[45]. Any disturbance (denaturation) of the native conforma-
tion, after secretion, is liable to expose hydrophobic “patches”
to aqueous solvent and is compensated for by hydrophobic
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protein/protein intermolecular interactions, manifest as
aggregation [46–48]. The phenomenon of conversion from
soluble to insoluble protein may be illustrated by lysozyme,
a highly soluble protein that has been studied as a structural
model for ∼100 years; in spite of its intrinsic solubility it is
readily denatured, under nonphysiologic conditions, to form
insoluble fibrils (amyloidosis). A more extreme example is
the phenomenon of prion disease in which the prion pro-
teins undergo a conformational change, in vivo, with the 𝛼
helix portion (54%) of its structure converting to a 𝛽 sheet
structure that renders it both insoluble and infectious;
that is, it can induce native prion protein to convert to the
insoluble/infectious form [48].
From the above it follows that if a P/GP proves to be
immunogenic, with the formation of ADA, it is likely due to
the presence of nonself forms resulting from denaturation,
the presence of inappropriate PTMs/CMs, and/or aggrega-
tion. Regulatory authorities have focused particularly on
aggregation as being the “beˆte noire.” Following extensive
studies a biologic therapeutic is formulated with excipients
selected to minimize denaturation and aggregate formation
over the shelf-life of the drug product; it is essential, therefore,
to physiochemically characterize the molecular size of drug
substance, drug product, and any aggregates present in the
approved material and to further monitor these parameters
over time [47, 49–55].
5. Potential Immunogenicity of
Antibody Therapeutics
Clinical experience has shown that even “fully” humanmAbs
are immunogenic, at least in a proportion of patients [56–
64]. An obvious explanation lies with the unique structure of
the mAb variable regions that comprise the paratope, formed
by the complementarity determining regions (CDRs) that
confer unique specificity.The variable regions of recombinant
mAb therapeutics are selected from libraries of antibody
genes expressed in (i) mice (chimeric); (ii) humanized chi-
meric mAbs; (iii) phage display libraries generated from an
outbred human population; (iv) humanized mice, and so
forth. In each case an approved mAb will present unique
structural features to an individual recipient (patient) and
may be recognized as foreign, with the generation of ADA.
Additional nonself structures may be present due to the
extensive polymorphism of genes encoding the constant
regions of IgG heavy chains and the constant regions of kappa
light chains that differs widely in their distribution between
ethnic populations [62–65]. To date only one polymorphic
form of each therapeutic mAb has been generated and
approved; therefore, there will be a high frequency mismatch
between the polymorphic variant of a given mAb therapeutic
and a proportion of patients. Additionally, since mAbs are
manufactured in xenogeneic tissue (hamster, CHO, mouse,
NS0, Sp20, etc.), drug substance and drug product may
lack the expression of some human CTMs and PTMs whilst
expressing others that are not present on human IgGs and
may contribute to immunogenicity [11, 56–66].
For the above reasons regulatory authorities demand
stringent postapproval pharmacovigilance and reporting of
adverse events [67–70]. A considerable literature suggests
that the immunogenicity of approved biologics may differ
between (i) individual biologics; (ii) manufacturer of the
same biologic; (iii) the physical form of the biologic; (iv)
patient population; (v) the disease entity; (vi) comorbidi-
ties; (vii) doe and route of administration; (vii) period of
administration, and so forth. Therefore, each approved mAb
therapeutic has to be evaluated on a case-by-case basis. It
is of interest to compare clinical experiences from admin-
istration of the anti-TNF therapeutics currently approved
for the treatment of inflammatory diseases, for example,
rheumatoid arthritis, Lupus, and Crohn’s disease [59–62].
Whilst the percentage of patients developing ADAmay differ
between reported studies and disease entities there is general
agreement that neutralising antibodies predominate [57, 58,
71]. The presence and specificity of neutralising ADA may
be demonstrated by the ability of a patient’s serum to inhibit
the binding of the mAb to TNF, for example, infliximab; the
same patient serum does not inhibit the binding of another
anti-TNFmAb, for example, adalimumabmAb, to TNF.Thus
if a patient becomes refractive to a given anti-TNF mAb
therapeutic, due to the generation of ADA, it may be possible
to effect disease remission by switching to an alternative anti-
TNF biologic. The formation of ADA may be ameliorated,
in a proportion of patients, by coadministration of a mild
immunosuppressant, for example, methotrexate [57, 58, 61,
71].
6. Aggregation of IgG Antibodies
Monoclonal human IgG antibodies have been available for
many decades as myeloma proteins, the products of plasma
cell tumours; however, their antigen specificities have not
been determined. The plentiful availability of these proteins
allowed for antigenic and structural definition of the IgG
subclasses, elucidation of Fc receptor recognition specifici-
ties, complement activation, and so forth.The first full length
sequence of an IgG molecule was determined for an IgG1
myeloma protein [72]. The lack of known antigen speci-
ficity did not allow for the generation of antigen/antibody
immune complexes (IC); therefore, aggregated forms of IgG
were generated as surrogate IC; common protocols included
heating at 60–70∘C, followed by high speed centrifugation
to yield a slightly opalescent solution [73] or cross-linking
by bifunctional small molecules 78. Rabbit antisera produced
to heat aggregated IgG revealed no new antigenic deter-
minants, compared to normal IgG, but responses to some
determinants were heightened [74].These early findings were
corroborated by a recent study of heat aggregated IgGs bind-
ing to each of the Fc𝛾R types, expressed as transmembrane
molecules on the surface of CHO cells [51].
The demonstration that aggregated forms of IgG could
function as surrogate IC has been interpreted in the modern
era to suggest that aggregated forms of biologic therapeutics
and mAbs in particular may be the principle immunogen
triggering the generation of ADA responses. Subsequently,
techniques and technologies for qualitative and quantita-
tive characterization of aggregated forms of IgG have been
developed and applied to analysis of IgG mAbs subjected
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to multiple protocols that each mimics conditions experi-
enced by a mAb throughout its production, formulation,
storage, and preparation for administration [75–78]. Amouse
mAb that was exposed to similar protocols proved to be
immunogenic when administered to a naive mouse; the
most immunogenic forms were relatively large, insoluble
aggregates that exhibited structural features of denatured
molecules [79]. It is presumed that aggregates are removed
from the circulation by phagocytic cells that degrade them
to generate peptides that may be presented by MHC Class II
molecules to B and T cells [50].
Thepropensity for amAb to aggregatemay be determined
by the unique structure of the variable regions superimposed
on an intrinsic susceptibility of the selected heavy and light
chain isotypes. An analysis of the constant regions of an
IgG1/kappa molecule identified partially exposed hydropho-
bic side chains that when in proximity to other hydropho-
bic residues constitute aggregation prone regions (APRs)
(“spatial-aggregation-propensity (SAP)”) [80]. APRs were
identified within the CH1, hinge, CH2, and CH3 domains of
the IgG1 heavy chain and the constant regions of both kappa
and lambda light chains; substitution of targeted hydrophobic
amino acids with selected hydrophilic residues generated
more stable proteinswith a diminished tendency to aggregate.
The APRs identified in IgG1 molecules are present also in the
IgG2, IgG3, and IgG4 subclass proteins [80–82].The presence
of “open” or “free” cysteine residues is another parameter
shown to result in the generation of aggregates, through inter-
molecular disulphide bond formation, under differing stress
conditions, and is particularly relevant for IgG2 subclass
proteins [83]. As expected the individual variable sequences
can have a profound impact on susceptibilities to aggregation.
The germline sequences for VH, VK, and VL have been com-
prehensively reviewed [84] and analysed for the aggregation
potential of their protein products [85]. These criteria may
now be applied to the selection of clones producing potential
IgG therapeutics. Close interrogation of the immunogenicity
of currently approved mAbs and biologics may reveal further
parameters that contribute to immunogenicity.
Recent studies have shown that the structure/form of a
mAb therapeutic must be considered beyond that of the for-
mulated drug product received by the pharmacy. Instructions
to pharmacists for resuspension of themAb therapeuticsHer-
ceptin and Avastin, for intravenous administration, specified
the use of 0.9% saline and specifically excluded of the use
of 5% dextrose solutions; no reason was given [86, 87]. The
consequences for contravening this instruction demonstrated
that titration of either Herceptin or Avastin in 5% dextrose
into human plasma or serum resulted in the formation
of insoluble aggregates [87]; possibly resulting in adverse
reactions on administration to patients and/or sensitising
them to later production of ADA. The phenomenon was
further investigated and it was shown that addition of a 5%
dextrose solution, at pH 6.0–6.2, to plasma/serum resulted
in the formation of aggregates of complement components
that then bound the mAb [88]. It was noted that instructions
for resuspension of Remicade specified 0.9% saline, pH 7.2,
conditions that did not result in the formation of complexes;
similarly, neither did Herceptin or Avastin; however, these
mAbs exhibit other instabilities at higher pH values [87–89];
for example, Asn 30 of Herceptin deamidates at pH > 5.0,
which lowers product bioactivity [4, 88].
7. Formation and Removal of Immune
Complexes (ICs)
It is axiomatic that an IgG antibody binds its target antigen
(pathogen!) to form an antigen/antibody immune complex
(IC). Similarly, it is axiomatic that the IC has to be removed
and destroyed. This is accomplished by cells that bear recep-
tors specific for the Fc region (Fc𝛾R) of the IgG molecule
(IgG-Fc) resulting in uptake and consequent destruction
within lysosomes. The peptides generated may bind to MHC
Class II molecules and subsequently be expressed on the
cell surface for presentation to helper CD4 T cells. This
promotes and amplifies a humoral immune response [90].
The integrity of the individual is dependent on tolerance
to self-molecules; however, tolerance has been shown to
be a dynamic ongoing process with activation/anergy being
dependent on the strength of binding of peptide bearing
MHC II molecules and helper T cells. Consequently, self-
reactive T cells and antibodies, usually of IgM isotype, can
be enumerated in normal healthy individuals.
The above summarizes the body’s protective response to
“foreign bodies” (pathogens) that gain access to tissue or
vascular sites. The aim of delivering a mAb therapeutic to a
patient is for it to bind its target antigen (self-molecule) with
the formation of IC that will activate mechanism of removal
and destruction similar to those activated by aggregated
P/GPs. I pose the following question therefore.
What Is the Difference between Aggregates and Immune Com-
plexes? An early study employed amatches set of recombinant
mAbs to evaluate the ability IC of each human antibody
class and subclass to trigger the neutrophil respiratory burst;
presumed to act through IgG-Fc receptors (Fc𝛾RI, Fc𝛾RIIA,
and Fc𝛾RIIIB), in both the presence and absence of comple-
ment [91, 92]. This and other studies demonstrated different
outcomes for each antibody isotype depending on the epitope
density and the antibody/antigen ratio at which ICs were
formed [28, 29, 93]. A further refinement has monitored the
binding of ICs, formed with antigens having differing epitope
densities, with a panel of CHO cells each expressing a single
Fc𝛾R type. This study also demonstrated that the avidity of
binding to Fc𝛾R increased with epitope density and revealed
a different order of Fc𝛾R binding from that reported for
studies of monomeric mAb binding to Fc𝛾R, [51]; that is,
the “received” Fc𝛾R binding specificities of the IgG subclasses
widely reported that the IgG subclasses are not an accurate
guide to the specificities of their IC in vivo. The fine epitope
specificity of a mAb can also have a determining impact
on the structure of the IC formed and resulting MoA, as
illustrated by approved anti-CD20 mAbs. Anti-CD20 mAbs
are classified as Type I or Type II depending on whether or
not they trigger redistribution of cell surface CD20 into lipid
rafts; Type I do so and as a result are able to activate the
complement cascade whilst Type II bind to individual CD20
tetramers only and do not activate complement [94, 95].
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The extracellular domain of the CD20 molecule is comprised
of only∼40 amino acids residues and crystallography demon-
strates that Type I and Type II antibodies bind overlapping
nonidentical epitopes.
A further example is provided by anti-TNFmAbs. Soluble
TNF exists as a trimer and is potentially trivalent for mAb
binding and able to form three-dimensional immune com-
plexes with divalent antibody. A study of the size distribution
of immune complex formed between TNF and the approved
anti-TNF biologics infliximab and etanercept, at differing
antigen/antibody ratios, showed that each antibody generated
immune complexes having a unique size profile [96]. It may
be presumed therefore that they will differ in their Fc𝛾R acti-
vating properties. It has been suggested that a fundamental
difference exits between IgG-ICs and aggregated IgG in that
the CDRs of the former are engaged but they are exposed in
the latter; however, X-ray crystal structural analysis of Fab-
antigen complexes shows that, for the majority of complexes
analysed, not all CDRs are engaged in antigen binding [97].
The above parametersmay be compounded by the fact that, in
contrast to most recombinant biologics, mAbs are delivered
at high doses (∼400mg); therefore, an unnatural or degraded
nonself component present at a level of 0.001% can constitute
a viable immunogenic dose [9, 98].
8. Chemical Modifications (CMs) of
Amino Acid Side Chains
N- and C-Terminal Residues. Unique N-terminal sequence
may be obtained for the heavy and light chains of most mon-
oclonal IgG paraprotein; however, for some, the N-terminal
amino acid yield may not be quantitative or may appear to be
entirely “blocked” [99]. This results when a gene encodes for
the incorporation of N-terminal glutamic acid or glutamine
residues thatmay subsequently cyclize, in vivo and/or in vitro,
with the generation of pyroglutamic acid (pGlu) [99–104].
The formation of pGlu in antibodies [101] and therapeutic
proteins is a concern for the biopharmaceutical industry
since it introduces charge heterogeneity and variations may
be considered to be evidence for lack of process control
[18]. Importantly, N-terminal pGlu is also implicated in
Alzheimer’s disease and dementia since it increases the
tendency for proteins to form insoluble fibrils; light chains are
particularly prone to the formation of pGlu fibrils [101, 105,
106]. As there is no evidence of benefit attached to the pres-
ence of N-terminal pGlu, to either the heavy or light chain,
it may be best to select against its presence, where possible,
during clone selection for a potential mAb therapeutic.
Sequencing studies reported the C-terminal residue of
serum derived IgG heavy chains to be glycine; however,
the IgG subclass genes encode a C-terminal lysine residue.
It was later shown that the lysine residue is cleaved, in
vivo, by an endogenous carboxypeptidase B. Recombinant
IgG molecules produced in mammalian cells exhibit mixed
populations of molecules with lysine present or absent on
each heavy chain and subsequent charge heterogeneity [107].
A concept paper produced by theEBE (EuropeanBiopharma-
ceutical Enterprises), a specialized group of EFPIA (European
Federation of Pharmaceutical Industries and Associations),
included the statements: “A number of scientific publications
suggest that C-terminal lysine truncation has no impact on
biological activity, PK/PD, immunogenicity and safety.” And
elsewhere in the document: “Lysine truncation does not
appear to adversely affect product potency or safety. However,
taking a conservative approach potential C-terminal lysine
effects on all antibodies cannot be ruled out. Thus, lysine
truncation should be characterized, and process consistency
should be demonstrated during product development; regu-
latory agencies suggest that C-terminal lysine content should
be reported for both the characterization and development
phases” [108]. Removal of C-terminal lysine results in the
presence of a C-terminal glycine residue that, when produced
in CHO cells, may be subject to amidation, introducing
further structural and charge heterogeneity [109]. A recent
report demonstrated that this has been circumnavigated by
genetically engineering CHO cells to “knock-down” expres-
sion of the peptidylglycine 𝛼-amidating monooxygenase
(PAM) enzyme [110]. The above comments and recommen-
dations are contradicted by a recent study that claimed that
IgG with C-terminal lysine constitutes a preform of the
molecule that prevents the formation of IgG hexamers that
can activate the complement cascade [111].
9. Cysteine and Disulphide Bond Formation
The gene sequence for the human IgG1 subclass protein Eu
encodes for 5 light chain and 9 heavy chain cysteine residues,
that is, 28 for the H2L2 heterodimer. The standard structural
cartoon for the human IgG1 protein (Eu) exhibits 12 intra-
chain and four interchain disulphide bridges. This general
pattern of intrachain disulphide bridge formation is main-
tained for each of the IgG subclasses; however, the number
of interchain bridges and their architecture vary between
and within the IgG subclasses [72, 112–118]. Heterogeneity of
disulphide bridge formation has been reported for normal
serum derived IgG, myeloma proteins, and recombinant
mAbs. Formation of the H2L2 dimer occurs following release
of heavy and light chains into the endoplasmic reticulum
(ER), with evidence that binding of the constant region of the
light chain (CL) to the heavy chain CH1 domain “catalyzes”
the generation of a correctly foldedH2L2 structure [112].This
nascent form explores multiple dynamic structures, with the
formation of native and nonnative disulphide bonds that are
transiently formed and reduced until a low energy confor-
mation is achieved [112, 113]; it should be noted that little
or no processing of the high mannose oligosaccharide will
have occurred at this point; therefore, the conformation of
the secreted IgG-Fc will not be achieved until oligosaccharide
processing is completed.
The IgG1molecule establishes the “standard” pattern with
two inter-heavy chain disulphide bridges and a single light-
heavy chain bridge; IgG2, IgG3, and IgG4 express 3, 11,
and 2 inter-heavy chain bridges, respectively. The cysteine
residues that form interchain disulphide bridges are clustered
within the hinge region and may be subject to reduction
and reformation when present in a reducing environment.
Heterogeneity in disulphide bond formation in IgG2 was first
reported for recombinant IgG2 proteins but, later, observed
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for normal serum derived IgG2 also [114–118]. The intercon-
version of these isoforms is dynamic and promoted by a
reducing environment provided by the presence of thiore-
doxin reductase, released into culture media by effete cells;
it can be ameliorated by control of dissolved oxygen levels
[114–118]. An in vitro model revealed that susceptibility to
reduction/oxidation differed between IgG subclasses and
light chain types with sensitivity being in the order IgG1𝜆 >
IgG1𝜅 > IgG2𝜆 > IgG2𝜅 [116].
A core hinge region sequence of -Cys-Pro-Pro-Cys-,
present in IgG1, IgG2, and IgG3, forms a partial helical struc-
ture that does not allow for intra-heavy chain disulphide
bridge formation; however, the homologous sequence in
the IgG4 subclass is -Cys-Pro-Ser-Cys- and this does allow
for intra-heavy chain disulphide bridge formation. Conse-
quently, natural and recombinant IgG4 antibody populations
are a mixture of molecules exhibiting inter- and intrahinge
heavy chain disulphide bridge isoforms [118–122]. The IgG4
form having intrahinge heavy chain bridges is susceptible to
dissociation into half-molecules (HL) that may reassociate
randomly to generate bispecific molecules; that is, a molecule
that is monovalent for two nonidentical antigens (epitopes);
this phenomenon is referred to as “Fab arm exchange.”
The exchange is also facilitated by presence of an arginine
residue at position 409 (R409) in the IgG4 heavy chain that
reduces noncovalent CH3/CH3 interactions, relative to the
presence of lysine 409 (K409) present in IgG1, IgG2, and IgG3
molecules. Lateral noncovalent interactions between the two
CH3 domains of R409 IgG4 are reduced such that, under
physiologic conditions and in the absence of hinge region
intra-heavy chain disulphide bridges, they dissociate to form
HL heteromonomers; a polymorphic variant of IgG4 exists
that has K409 residue and is not subject to Fab arm exchange
[120–122].
10. Oxidation of Methionine
Methionine residues exposed, or partially exposed, on the
surface of native or denatured proteins may be susceptible
to oxidation. Methionine residues within variable region
framework sequences of mAbs have not been reported to be
vulnerable to oxidation but residues exposed within CDRs
have been [123–127]. Consequently, sequencing of prospec-
tive clones is advised to inform selection and rejection of
clones having methionine within CDRs. It has been shown
that methionine residues M252 and M428 of IgG1 and IgG2
subclass proteins are susceptible to oxidation [123]. Although
these residues are distant from each other in linear sequence,
they are conformationally proximal, at the CH2/CH3 inter-
face. The interaction site for the neonatal Fc receptor (FcRn),
SpA, and SpG is similarly localised to the CH2/CH3 interface
andM252 andM428 oxidation has been shown to reduce the
affinity of binding to these ligands and to reduce catabolic
half-life [124–127]. Minimal levels of M252 oxidation (2–5%)
are reported for IgGmAbs held in formulation buffers, whilst
lower levels of oxidation are reported for M428; however,
oxidation of these residues increases under conditions of
accelerated stability testing and on prolonged storage [123].
Analysis of Herceptin, obtained from a pharmacy, and a
potential biosimilar demonstrated that care has to be exer-
cised when resuspending this mAb therapeutic since a
discrepancy was observed for the level of M252 oxidation
between the innovator product (4.39%) and the proposed
biosimilar (10.33%) [128].
11. Deamidation: Asparagine and Glutamine
Deamidation of asparagine and glutamine residues generates
aspartic acid, isoaspartic acid, or glutamic acid, respectively,
and is a frequently encountered PTM [9, 10, 129, 130]. Deam-
idation of asparagine residues is influenced by adjacent amino
acid residues, particularly the presence of a glycine residue
C-terminal to the asparagine [-N-G-] and the degree of
exposure to external environments. Studies of IgG1 and IgG2
proteins, in vitro and in vivo, have shown that asparagine
residues 315 and 384 are susceptible to deamidation with the
formation of isoaspartic and aspartic acid residues, respec-
tively [129–134]. The relative susceptibility to deamidation at
these sites varied between studies; however, the significance
may be ameliorated by the finding that ∼23% of asparagine
384 residues of normal polyclonal IgG are deaminated to
aspartic acid; thus it may be assumed that healthy humans are
constantly exposed to IgG bearing this PTM and that it might
be considered to be a “self” structure. These studies did not
identify asparagine deamidation within the constant region
of the kappa light chains.
By contrast deamidation within variable regions, particu-
larlywithinCDRs, of recombinant antibodies has been shown
to compromise antibody specificity and/or binding affinity
[131–134]. Interestingly, the approved blockbuster antibody
therapeutic Trastuzumab (Herceptin) has asparagine residues
in light chain CDR1 (Asn 30) and heavy chain CDR2 (Asn 55)
that were shown to be susceptible to deamidation on accel-
erated degradation studies [4, 13]; the approved drug sub-
stance did not exhibit deamidation of these residues; there-
fore, their presence or absence could be used as a lot release
criterion [134]. As previously discussed the levels of deamida-
tion of asparagine residues, both within variable and constant
regions, of a proposed Herceptin biosimilar were higher than
that reported for the innovator molecule [128] underlining
the susceptibility to deamidation of these residues and the
care that has to be exercised when resuspending this antibody
therapeutic.
Glutamine residues are relatively resistant to deamidation
and no glutamine residues were reported to be subject to
deamidation under nondenaturing conditions [8, 13]. Under
conditions of accelerated degradation six Gln residues of a
mAb were shown to be susceptible to deamination: four in
variable regions and residues 295 and 418 in the IgG-Fc [8].
The cyclization of N-terminal glutamine to form pyroglu-
tamic acids has been discussed, above.
12. 𝛾-Carboxylation and 𝛽-Hydroxylation
The function of proteins of the blood coagulation systemmay
be dependent on 𝛾-carboxylation and 𝛽-hydroxylation [135–
138]. Both PTMs contribute to the binding of calcium ions
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and are important, and in some cases essential, for blood
factors VII, IX, and X, activated protein C, and protein S of
the anticoagulant system. These proteins are comprised of
structurally distinct domains with the N-terminal Gla
(gamma-carboxyglutamic acid-rich) domain providing 𝛾-
carboxylation sites and the EGF (epidermal growth factor-
like) domains the 𝛽-hydroxylation sites. Typically Gla
domains are approximately 45 amino acids long and contain
9–12Gla residues. Carboxylation of Gla domain glutamate
residues is not dependent upon occurrence within a specific
consensus sequence, but carboxylase binding is mediated
by an immediately adjacent propeptide region, which is
subsequently removed by proteolysis [135–137].
Hydroxylation of target EGF domain aspartate or aspar-
agine residues is catalyzed by a 𝛽-hydroxylase located in the
ER. EGF domains are ∼45 amino acids long and contain
one potential hydroxylation site. Hydroxylation is consensus
sequence dependent and is usually partial, with only a frac-
tion of target molecules being hydroxylated. Full carboxyla-
tion and hydroxylation, on the other hand, are essential to
maintaining biological activity of protein C [136–139]. The
native molecule displays nine carboxylation and one hydrox-
ylation sites. Such stringent PTM requirements could not be
met by CHO cells, forcing the developers of the recombinant
proteins of the coagulation system to develop a modified
human cell line (HEK 293) for their manufacture [138].
13. Sulphation
Sulphation is a PTMpredominantly associatedwith secretory
and membrane proteins [140]. The attachment of a sulphate
(SO3−) group to an oxygen atom of tyrosine, serine, or threo-
nine residues is effected by a sulfotransferases enzyme present
in the trans-Golgi network [141]. In the context of biophar-
maceuticals native hirudin (a leech-derived anticoagulant)
and blood factors VIII and IX are usually sulphated. Neither
of the approved recombinant forms of hirudin are sulphated
although it has been shown that sulphated hirudin (at
Tyr63) displays 10-fold tighter affinity for thrombin than do
unsulphated analogues [142].Whilst over 90%of native factor
IX molecules are sulphated, less than 15% of the approved
recombinant form are, with apparently little if any difference
in product efficacy [143]. Sulphation of factor VIII is required
for optimal binding to its plasma carrier protein (von Wille-
brand’s factor) and, interestingly, people inheriting a factor
VIII Tyr1680→Phemutation often displaymild haemophilia
[140]. Several hormone cell surface receptors are known to be
tyrosine sulphated, and sulphation is required for high affinity
ligand binding and subsequent receptor activation [144, 145].
14. Glycosylation: Immunogenic Glycoforms
Produced by Rodent Cell Lines
The impact of glycosylation on secretion, stability, function,
and immunogenicity of recombinant GPs remains a focal
point within the biopharmaceutical industry. The glycoform
profile of a GP may be species, cell type, and, possibly, sex
specific. Recombinant EPO (rEPO) when first produced in
CHO cells exhibited increased biologic activity compared to
the natural product in vitro; however, in vivo studies showed
a very low level of biological function. It was shown that
this was due to rapid clearance in the liver, via the asialo
glycoprotein receptor, due to the oligosaccharide chains not
being “capped” with terminal sialic acid residues. Successful
generation of appropriately sialylated rEPO was achieved
and Epogen was approved in 1989 [2]. Since that time many
improvements have been introduced, including protein engi-
neering to introduce additional glycosylation sites [146, 147].
The nonhuman production platforms employed, for example,
CHO, NS0, and Sp2/0 cells which may add sugar residues
that are foreign to humans and consequently confer immuno-
genicity.
The prototype IgG antibody molecule bears oligosac-
charide N-linked to asparagine residue 297 of the IgG-Fc
heavy chain. Although the presence or absence of IgG-Fc
oligosaccharide does not affect antigen binding specificity,
it has been reported to modulate binding affinity. Its main
impact is to modulate activation of downstream effector
functions that eliminate and destroy antibody/pathogen ICs;
mAb therapeutics may be “customised” to activate the same
effector mechanisms for the elimination of cancer cells, and
so forth [11, 148]. The oligosaccharide released from normal
polyclonal IgG-Fc is heterogeneous and essentially comprised
of the core heptasaccharide with the variable addition of
fucose, galactose, bisecting N-acetylglucosamine, and N-
acetylneuraminic (sialic) acid residues [9, 11, 148–150]. Early
analytical studies revealed variations in the content of galac-
tose residues and G0 (zero galactose), G1, and G2 glycoforms
were enumerated; however, it was later shown that whilst a
majority of IgG-Fc oligosaccharides bore fucose residues, a
significant proportion did not; therefore a revision of glyco-
form designations was required; thus G0, G1, and G2 refer
to IgG-Fc oligosaccharides that do not include fucose, whilst
G0F, G1F, and G2F refer to oligosaccharides bearing both
fucose and galactose; when bisecting N-acetylglucosamine
is present a B is added, for example, G0B, G0BF, and G1BF;
sialylation at the galactose residues is designated as G1FS,
G2FBS, and so forth.The approximate composition of neutral
oligosaccharides released from normal polyclonal human
IgG-Fc is G0: 3%; G1: 3%; G2: 6%; G0F: 23%; G1F: 30%;
G2F: 24%; G0BF: 3%; G1BF: 4%; and G2BF: 7% [9, 11, 22–
24, 148–151]. It is important to define the glycoform of the
intact IgGmolecule, for example, [G0/G1F] and [G1F/G2BF],
since it has been shown that individual IgG molecules may
be comprised of symmetrical or asymmetrical heavy chain
glycoform pairs [152, 153]. Recombinant mAbs expressing
each of the naturally occurring IgG-Fc glycoforms have been
generated to determine their respective abilities to activate a
range of effector mechanisms; in addition truncated, aglyco-
sylated, and novel glycoforms have been generated that have
contributed to our understanding of the role of glycosylation
in the interactions of IgG-Fc with effector ligands [11, 22, 148–
155].
The glycosylation profile of each approved mAb thera-
peutic is identified as a CQA, whether the aim is to optimise
or minimize effector function potential, that is, the MoA.
The first criterion is therefore to produce a mAb having
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either 100% or 0% oligosaccharide occupancy. The CHO,
NS0, and Sp2/0 cell lines used for the production of mAbs
produce predominantly G0F heavy chain glycoforms with
relatively low levels of galactosylated and nonfucosylated
IgG-Fc, relative to normal polyclonal IgG-Fc; however, pre-
cise culture conditions may impact the glycoform profile of
the product [22, 156–159]. Unfortunately, these production
cell lines may also add sugars that are not expressed on
human glycoproteins andmay be immunogenic.Thus, whilst
CHO cell lines may add N-acetylneuraminic acid residues
they do so in 𝛼(2-3) linkage, rather than the 𝛼(2–6) linkage
present in human IgG-Fc. A particular concern is that the
addition, by NS0 and Sp2/0 cells, of galactose in 𝛼(1–3)
linkage to galactose linked𝛽(1–4) to theN-acetylglucosamine
residues [160–163]. Humans and higher primates do not have
a functional gene encoding the transferase that adds galactose
in 𝛼(1–3) linkage; however, due to continual environmental
exposure to the gal 𝛼(1–3) gal epitope, for example, in
red meats, humans develop IgG antibodies specific to this
antigen; a proportion of individuals develop IgE antibodies
and incidences of immediate hypersensitivity reactions have
been reported, some resulting in death [160, 161]. The gal
𝛼(1–3) gal epitope is widely expressed on hamster cells and
some derived CHO cell lines have been shown to be capable
of (gal 𝛼(1–3) gal) addition [163]. Similarly, CH0, NS0,
and Sp2/0 cells may add an N-glycolylneuraminic acid, in
𝛼(2-3) linkage that also may be immunogenic in humans
[156–163]. A significant population of normal human IgG-
Fc bears a bisecting N-acetylglucosamine residue that is
absent from IgG-Fc produced in CHO, NS0, or Sp2/0 cells.
Studies of homogeneous IgG-Fc glycoforms, generated in
vitro, have shown qualitative and quantitative differences in
effector function activities between the IgG subclasses and
for differing glycoforms within each subclass [11, 64, 164–
166]. It has not proved possible tomanipulate culturemedium
conditions to generate predetermined homogeneous mAb
glycoform profiles; however, significant “tweaking” of the
profile can be achieved during a production run [158, 159]
and cellular engineering has been employed to enhance pro-
duction of particular human IgG-Fc glycoforms.
15. Summary and Conclusions
The thrust of this review is that natural P/GPs are structurally
heterogeneous and comprised of multiple isoforms, due to
variations in CTMs, PTMs, and CMs. The isoform composi-
tion of the proteomemay differ between individuals and, over
time, within individuals; however, the integrity of the individ-
ual ismaintained by functional immunological tolerance.The
production of a recombinant P/GP in a heterologous system
will inevitably result in the generation of isoforms structurally
different to endogenous P/GPs that may be perceived by
the immune system as nonself and result in an immune
response with the production of ADA that compromise ther-
apeutic benefit and/or induce adverse events. Recombinant
mAbs presents a particular challenge because an endogenous
molecule is not available for structural comparison; that is,
they are, by definition, structurally and functionally unique.
Multiple parameters that may impact on immunogenicity
have been discussed with a particular emphasis on denatu-
ration leading to the formation of immunogenic aggregates.
Whilst this has validity for recombinant P/GP therapeutics
in general, it may not be so evident for mAbs since their
MoA depends on the formation of ICs that are themselves
aggregates. The size and architecture of IC aggregates (ICA)
formed are dependent on multiple parameters, including
affinity and antigen/mAb ratio.
It is held that on chronic exposure all recombinant P/GPs
are immunogenic, at least in a proportion of patients; how-
ever, the incidence and consequences of immunogenicity
may vary depending on the disease treated. Treatments
for cancer include drugs that target dividing cells with
the inevitable collateral consequence of compromising the
immune system, that is, immunosuppression; thus short term
exposure to a mAb in the treatment of cancers may not
occasion the generation of ADA. In contrast treatment of
chronic diseases with mAb may result in repeated episodes
of remission and relapse over extended time periods and
has been shown to increase the incidence of development
of ADA. A palliative measure may be to induce a low level
of immunosuppression. This has been realized for rheumatic
diseases with exposure to the mild immunosuppressant
methotrexate and anti-TNF mAb [167, 168]. Early studies
established that immunological tolerance can be induced
experimentally by exposure to aggregate free forms of a
potential immunogen [169, 170]; this potential has been
exploited clinically to reduce the incidence of ADA formation
in patients receiving the mAb Alemtuzumab. A single amino
acid mutant of the antibody was generated that resulted in
loss of antigen binding activity 178. Exposure of patients to a
high dose of this mutant prior to dosing with the active anti-
body reduced the incidence of immunogenicity from ∼74%
to 21% [29, 170, 171]. The crucial difference between Alem-
tuzumab and themutant was that the latter is not able to form
ICs, thus demonstrating the generation of ICs as a parameter
contributing to immunogenicity; that is, the outcome of
exposure to ICs and aggregates may be equivalent. This
suggests that in addition to characterizing aggregated forms
of mAb in drug product, assumed to be present at the time
of administration, studies of the structure and function of
ICs formed on administration of mAb should be investigated
[86–88]; the necessary tools are now available [172–176].
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